Physician profile
Atta U Butt
NPI 1083727317
$4,554.59
in general payments reported to CMS, 2019-2025
33 companies · $627 in 2025
The $627 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $910 · 2021: $958 · 2022: $483 · 2023: $402 · 2024: $658 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $821.92 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $435.22 | 2019-2025 | |
| Abbvie INC. | $419.41 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $335.19 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $288.32 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.85 | 2020-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.58 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $252.54 | 2019-2022 | |
| Novo Nordisk INC | $235.60 | 2019-2021 | |
| Amarin Pharma, INC. | $231.16 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $172.56 | 2019-2024 | |
| Boston Scientific Corporation | $127.24 | 2025 | Watchman Access System, Watchman Flx |
| Amgen INC. | $81.21 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Abbott Laboratories | $62.03 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $59.27 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $56.12 | 2022 | |
| Dexcom, INC. | $55.32 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.22 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $44.67 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $28.36 | 2024 | |
| Mylan Specialty L.P. | $27.44 | 2023 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $26.49 | 2022 | |
| Astellas Pharma US INC | $23.68 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.73 | 2021 | |
| Dermira, INC. | $22.69 | 2020 | |
| Radius Health, INC. | $19.10 | 2021 | |
| Lucid Diagnostics INC. | $18.64 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.12 | 2021 | |
| Melinta Therapeutics, LLC | $18.00 | 2019 | |
| Sumitomo Pharma America, INC. | $16.37 | 2025 | Gemtesa |
| Medtronic Vascular, INC. | $13.11 | 2020 | |
| Sanofi Pasteur INC. | $12.36 | 2019 | |
| Insmed, INC. | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atta Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.